Moderna (MRNA) Competitors

In the previous week, Robinhood Markets had 25 more articles in the media than Moderna. MarketBeat recorded 64 mentions for Robinhood Markets and 39 mentions for Moderna. Robinhood Markets' average media sentiment score of 0.30 beat Moderna's score of 0.25 indicating that Robinhood Markets is being referred to more favorably in the news media.

Robinhood Markets has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Robinhood Markets, indicating that it is currently the more affordable of the two stocks.

Moderna has a beta of 1.09, suggesting that its share price is 9% more volatile than the broader market. Comparatively, Robinhood Markets has a beta of 2.35, suggesting that its share price is 135% more volatile than the broader market.

75.3% of Moderna shares are held by institutional investors. Comparatively, 93.3% of Robinhood Markets shares are held by institutional investors. 10.8% of Moderna shares are held by insiders. Comparatively, 13.5% of Robinhood Markets shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Robinhood Markets has a net margin of 42.01% compared to Moderna's net margin of -141.43%. Robinhood Markets' return on equity of 22.43% beat Moderna's return on equity.

Moderna presently has a consensus price target of $78.17, suggesting a potential downside of 60.32%. Robinhood Markets has a consensus price target of $133.71, suggesting a potential upside of 24.95%. Given Robinhood Markets' stronger consensus rating and higher probable upside, analysts clearly believe Robinhood Markets is more favorable than Moderna.

Novavax has lower revenue, but higher earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks.

Novavax has a net margin of -59.87% compared to Moderna's net margin of -141.43%. Novavax's return on equity of -14.82% beat Moderna's return on equity.

75.3% of Moderna shares are owned by institutional investors. Comparatively, 53.0% of Novavax shares are owned by institutional investors. 10.8% of Moderna shares are owned by company insiders. Comparatively, 1.6% of Novavax shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Moderna currently has a consensus target price of $78.17, suggesting a potential downside of 60.32%. Novavax has a consensus target price of $14.00, suggesting a potential upside of 27.16%. Given Novavax's stronger consensus rating and higher probable upside, analysts plainly believe Novavax is more favorable than Moderna.

In the previous week, Moderna had 10 more articles in the media than Novavax. MarketBeat recorded 39 mentions for Moderna and 29 mentions for Novavax. Moderna's average media sentiment score of 0.25 beat Novavax's score of 0.06 indicating that Moderna is being referred to more favorably in the media.

Moderna has a beta of 1.09, indicating that its stock price is 9% more volatile than the broader market. Comparatively, Novavax has a beta of 2.44, indicating that its stock price is 144% more volatile than the broader market.

Ocugen has lower revenue, but higher earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks.

Moderna presently has a consensus price target of $78.17, suggesting a potential downside of 60.32%. Ocugen has a consensus price target of $9.50, suggesting a potential upside of 871.97%. Given Ocugen's stronger consensus rating and higher possible upside, analysts clearly believe Ocugen is more favorable than Moderna.

In the previous week, Moderna had 29 more articles in the media than Ocugen. MarketBeat recorded 39 mentions for Moderna and 10 mentions for Ocugen. Ocugen's average media sentiment score of 0.80 beat Moderna's score of 0.25 indicating that Ocugen is being referred to more favorably in the news media.

Moderna has a beta of 1.09, meaning that its stock price is 9% more volatile than the broader market. Comparatively, Ocugen has a beta of 2.27, meaning that its stock price is 127% more volatile than the broader market.

Ocugen has a net margin of 0.00% compared to Moderna's net margin of -141.43%. Moderna's return on equity of -28.30% beat Ocugen's return on equity.

75.3% of Moderna shares are held by institutional investors. Comparatively, 10.3% of Ocugen shares are held by institutional investors. 10.8% of Moderna shares are held by insiders. Comparatively, 4.0% of Ocugen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Moderna had 14 more articles in the media than Regeneron Pharmaceuticals. MarketBeat recorded 39 mentions for Moderna and 25 mentions for Regeneron Pharmaceuticals. Regeneron Pharmaceuticals' average media sentiment score of 0.39 beat Moderna's score of 0.25 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the media.

Regeneron Pharmaceuticals currently has a consensus price target of $817.92, indicating a potential upside of 10.59%. Moderna has a consensus price target of $78.17, indicating a potential downside of 60.32%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Regeneron Pharmaceuticals is more favorable than Moderna.

83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 75.3% of Moderna shares are owned by institutional investors. 7.0% of Regeneron Pharmaceuticals shares are owned by insiders. Comparatively, 10.8% of Moderna shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Regeneron Pharmaceuticals has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Regeneron Pharmaceuticals has a beta of 0.16, indicating that its stock price is 84% less volatile than the broader market. Comparatively, Moderna has a beta of 1.09, indicating that its stock price is 9% more volatile than the broader market.

Regeneron Pharmaceuticals has a net margin of 27.86% compared to Moderna's net margin of -141.43%. Regeneron Pharmaceuticals' return on equity of 13.47% beat Moderna's return on equity.